» Articles » PMID: 34064909

Targeting the NLRP3 Inflammasome As a New Therapeutic Option for Overcoming Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Jun 2
PMID 34064909
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammasomes are multiprotein complexes that regulate the maturation and secretion of the proinflammatory cytokines interleukin-1beta (IL-1β and interleukin-18 (IL-18) in response to various intracellular stimuli. As a member of the inflammasomes family, NLRP3 is the most studied and best characterized inflammasome and has been shown to be involved in several pathologies. Recent findings have made it increasingly apparent that the NLRP3 inflammasome may also play a central role in tumorigenesis, and it has attracted attention as a potential anticancer therapy target. In this review, we discuss the role of NLRP3 in the development and progression of cancer, offering a detailed summary of NLRP3 inflammasome activation (and inhibition) in the pathogenesis of various forms of cancer. Moreover, we focus on the therapeutic potential of targeting NLRP3 for cancer therapy, emphasizing how understanding NLRP3 inflammasome-dependent cancer mechanisms might guide the development of new drugs that target the inflammatory response of tumor-associated cells.

Citing Articles

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer.

Niu N, Li K, Wang J, Funes V, Espinoza B, Li P Biomark Res. 2025; 13(1):21.

PMID: 39871312 PMC: 11773940. DOI: 10.1186/s40364-024-00721-7.


Cholesterol crystals in the pathogenesis of atherosclerosis.

Baumer Y, Irei J, Boisvert W Nat Rev Cardiol. 2024; .

PMID: 39558130 DOI: 10.1038/s41569-024-01100-3.


Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition.

Tang C, Guo X, Li Y, Yi Y, Tang Z, Zhang Q Mediators Inflamm. 2024; 2024:8828367.

PMID: 39144184 PMC: 11324363. DOI: 10.1155/2024/8828367.


The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan's National Health Insurance Research Database.

Yeh J, Liw P, Wong Y, Kao H, Lee C, Lin C Eur J Med Res. 2024; 29(1):245.

PMID: 38649928 PMC: 11034118. DOI: 10.1186/s40001-024-01836-1.


Amino Sugar-Enriched Fraction of Korean Red Ginseng Extract Induces the Priming Step of NLRP3 Inflammasome.

Ahn H, Lee G Molecules. 2024; 29(7).

PMID: 38611734 PMC: 11013037. DOI: 10.3390/molecules29071455.


References
1.
Veeranki S . Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis. Cell Mol Biol Lett. 2013; 18(3):355-67. PMC: 6275599. DOI: 10.2478/s11658-013-0095-y. View

2.
Gurung P, Anand P, Malireddi R, Vande Walle L, Van Opdenbosch N, Dillon C . FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J Immunol. 2014; 192(4):1835-46. PMC: 3933570. DOI: 10.4049/jimmunol.1302839. View

3.
Segovia-Mendoza M, Morales-Montor J . Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology. Front Immunol. 2019; 10:348. PMC: 6407672. DOI: 10.3389/fimmu.2019.00348. View

4.
Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y . A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013; 85(10):1504-12. DOI: 10.1016/j.bcp.2013.03.008. View

5.
Karan D, Tawfik O, Dubey S . Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer. Sci Rep. 2017; 7(1):4378. PMC: 5491527. DOI: 10.1038/s41598-017-04286-4. View